诱导化疗±同期放化疗对血浆EBV-DNA>4000 copies/ml的N<sub>2-3</sub>M<sub>0</sub>期鼻咽癌的临床研究

doi:10.3760/cma.j.issn.1004-4221.2017.02.002

摘要
图/表
参考文献()
相关文章 (10)
点击分布统计
下载分布统计

全文: PDF (843 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

摘要目的探讨诱导化疗在血浆EBV-DNA>4000 copies/ml的N_2-3M₀期鼻咽癌治疗中的价值。方法回顾分析2009—2013年间收治的210例血浆EBV-DNA>4000 copies/ml的N_2-3M₀期鼻咽癌患者的临床资料,101例行诱导化疗+同期放化疗(NCRT),109例行同期放化疗(CCRT)。Kaplan-Meier法计算生存率并Logrank检验和单因素分析诱导化疗后血浆EBV-DNA水平变化对预后的影响。结果 3年样本数为154例。NCRT组和CCRT组3年OS、DFS、DMFS分别为88.0%和80.4%(P=0.210)、80.1%和70.6%(P=0.029)、87.1%和76.0%(P=0.036)。N₂期NCRT组3年DFS、DMFS高于CCRT组(P=0.031、0.014),N₃期NCRT组3年OS、DFS、DMFS高于CCRT组(P=0.029、0.012、0.019)。全组诱导化疗2、3、4个周期的3年OS、DMFS依次提高(P=0.020、0.021)。NCRT组放疗前诱导化疗2、3、4个周期后血浆EBV-DNA转阴率分别为51.85%、76.92%、88.57%(P=0.004),将上述血浆EBV-DNA水平降为0作为预测进展指标的敏感性分别为62.50%、66.67%、75.00%(P=0.910),特异性分别为57.89%、90.00%、96.77%(P=0.000)。结论诱导化疗提高EBV-DNA>4000 copies/ml的N_2-3M₀期鼻咽癌患者的DFS、DMFS和N₃期OS,不提高RFS。诱导化疗疗程与预后呈正比。随着诱导化疗周期增加血浆EBV-DNA转阴率逐渐增加,4个周期化疗后血浆EBV-DNA降0作为预测进展指标的敏感性和特异性均优于其他两组。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	陈俊妮
	吴刚
	杨时平
	张帅
	林洁
	王奋
	林少民

关键词 ：鼻咽肿瘤/诱导化学疗法, 鼻咽肿瘤/同期放化疗法, EB病毒, 脱氧核糖核酸

Abstract：Objective To investigate the value of induction chemotherapy in the treatment of stage N_2-3M₀ nasopharyngeal carcinoma with plasma Epstein-Barr virus (EBV) DNA>4000 copies/ml. Methods A retrospective study was performed on clinical data from 210 patients with stage N_2-3M₀ nasopharyngeal carcinoma and plasma EBV DNA>4000 copies/ml who were admitted to our hospital from 2009 to 2013. In the 210 patients, 101 received induction chemotherapy plus concurrent chemoradiotherapy (NCRT) and 109 concurrent chemoradiotherapy alone (CCRT). The survival rates were calculated by the Kaplan-Meier method. The log-rank test was used for the analysis of survival rates and univariate analysis of the impacts of the changes in the plasma EBV DNA level after induction chemotherapy on the prognosis. Results The 3-year sample size was 154.The NCRT group had significantly higher 3-year disease-free survival (DFS) and distant metastasis-free survival (DMFS) rates than the CCRT group (80.1% vs. 70.6%, P=0.029;87.1% vs. 76.0%, P=0.036), while there was no significant difference in 3-year overall survival (OS) rate between the two groups (88.0% vs. 80.4%, P=0.210). Patients with stage N₂ disease in the NCRT group had significantly higher 3-year DFS and DMFS rates than those in the CCRT group (P=0.031,0.014). Patients with stage N₃ disease in the NCRT group had significantly higher 3-year OS, DFS, and DMFS rates than those in the CCRT group (P=0.029,0.012,0.019). In all the patients, the 3-year OS and DMFS rates were improved with the increase in the cycle number of induction chemotherapy (P=0.020,0.021). In the NCRT group, patients treated with 2, 3, and 4 cycles of induction chemotherapy before radiotherapy had plasma EBV-DNA clearance rates of 51.85%, 76.92%, and 88.57%, respectively (P=0.004). Using the complete clearance of plasma EBV-DNA as a predictor of progression, the sensitivity for the above three groups was 62.50%,66.67% and 75.00(P=0.910), respectively, and the specificity was 57.89%,90.00% and 96.77%(P=0.000), respectively. Conclusions In the treatment of nasopharyngeal carcinoma with plasma EBV DNA>4000 copies/ml, induction chemotherapy improves DFS and DMFS in patients with stage N_2-3M₀ disease and OS in patients with stage N₃ disease;induction chemotherapy dose not improve recurrence-free survival rate. The prognosis and plasma EBV DNA clearance rate are improved with the increase in the cycle number of induction chemotherapy. Using the complete clearance of plasma EBV DNA as a predictor of progression, the sensitivity and specificity in patients treated with 4 cycles of chemotherapy are superior over those in patients treated with 2 or 3 cycles of chemotherapy.

Key words： Nasopharyngeal neoplasms/induction chemotherapy Nasopharyngeal neoplasms/concurrent chemo-radiotherapy Epstein-Barr virus Deoxyribonucleic acid

收稿日期: 2016-04-29

引用本文:

陈俊妮,吴刚,杨时平等. 诱导化疗±同期放化疗对血浆EBV-DNA>4000 copies/ml的N_2-3M₀期鼻咽癌的临床研究[J]. 中华放射肿瘤学杂志, 2017, 26(2): 123-127.

Chen Junni,Wu Gang,Yang Shipiing et al. A clinical study of induction chemotherapy±concurrent chemoradiotherapy for stage N_2-3M₀ nasopharyngeal carcinoma with plasma Epstein-Barr virus DNA>4000 copies/ml[J]. Chinese Journal of Radiation Oncology, 2017, 26(2): 123-127.

链接本文:

http://journal12.magtechjournal.com/Jweb_fszlx/CN/10.3760/cma.j.issn.1004-4221.2017.02.002 或 http://journal12.magtechjournal.com/Jweb_fszlx/CN/Y2017/V26/I2/123

[1] 徐敏,林焕新,孙蕊,等.1992分期与2008分期对初治鼻咽癌患者远处转移的预测价值[J].中华肿瘤防治杂志,2010,17(16):1293-1297.
Xu M,Lin HX,Sun R,et al. Value of predicting metastasis by 1992 staging system and 2008 staging system in nasopharyngeal carcinoma patients[J].Chin J Cancer Prev Treat,2010,17(16):1293-1297.
[2] Feng BJ,Huang W,Shugart YY,et al. Genome-wide scan for familial nasopharyngeal carcinoma reveals evidence of linkage to chromosome 4[J].Nat Genet,2002,31(4):395-399.DOI:10.1038/ng932.
[3] Zeng MS,Li DJ,Liu QL,et al. Genomic sequence analysis of Epstein-Barr virus strain GD1 from a nasopharyngeal carcinoma patient[J].J Virol,2005,79(24):15323-15330.DOI:10.1128/JVI.79.24.15323-15330.2005.
[4] Lo YMD,Chan LYS,Lo KW,et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma[J].Cancer Res,1999,59(6):1188-1191.
[5] Chen WH,Tang LQ,Guo SS,et al. Prognostic value of plasma Epstein-Barr virus DNA for local and regionally advanced nasopharyngeal carcinoma treated with cisplatin-based concurrent chemoradiotherapy in intensity-modulated radiotherapy era[J].Medicine,2016,95(5):e2642.DOI:10.1097/MD.0000000000002642.
[6] Zhao FP,Liu X,Chen XM,et al. Levels of plasma Epstein-Barr virus DNA prior and subsequent to treatment predicts the prognosis of nasopharyngeal carcinoma[J].Oncol Lett,2015,10(5):2888-2894.DOI:10.3892/ol.2015.3628.
[7] Yip TTC,Ngan RKC,Fong AHW,et al. Application of circulating plasma/serum EBV DNA in the clinical management of nasopharyngeal carcinoma[J].Oral Oncol,2014,50(6):527-538.DOI:10.1016/j.oraloncology.2013.12.011.
[8] Hui EP,Ma BB,Leung SF,et al. Randomized phase Ⅱ trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma[J].J Clin Oncol,2009,27(2):242-249.DOI:10.1200/JCO.2008.18.1545.
[9] Ouyang PY,Xie C,Mao YP,et al. Significant efficacies of neoadjuvant and adjuvant chemotherapy for nasopharyngeal carcinoma by meta-analysis of published literature-based randomized,controlled trials[J].Ann Oncol,2013,24(8):2136-2146.DOI:10.1093/annonc/mdt146.
[10] Tan T,Lim WT,Fong KW,et al. Concurrent Chemo-Radiation with or without induction gemcitabine,carboplatin,and paclitaxel:a randomized,phase 2/3 trial in locally advanced nasopharyngeal carcinoma[J].Int J Radiat Oncol Biol Phys,2015,91(5):952-960.DOI:10.1016/j.ijrobp.2015.01.002.
[11] Zhang LN,Gao YH,Lan XW,et al. Effect of taxanes-based induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma:a large scale propensity-matched study[J].Oral Oncol,2015,51(10):950-956.DOI:10.1016/j.oraloncology.2015.07.004.
[12] Chen YP,Guo R,Liu N,et al. Efficacy of the additional neoadjuvant chemotherapy to concurrent chemoradiotherapy for patients with locoregionally advanced nasopharyngeal carcinoma:a Bayesian network meta-analysis of randomized controlled trials[J].J Cancer,2015,6(9):883-892.DOI:10.7150/jca.11814.
[13] 刘晓清,罗伟,刘孟忠,等.1093例初治鼻咽癌的疗效和预后分析[J].中华放射肿瘤学杂志,2008,17(2):81-86.DOI:10.3321/j.issn:1004-4221.2008.02.001.
Liu XQ,Luo W,Liu MZ,et al. Treatment results and prognostic analysis of 1093 primary nasopharyngeal carcinoma[J].Chin J Radiat Oncol,2008,17(2):81-86.DOI:10.3321/j.issn:1004-4221.2008.02.001.
[14] Zheng W,Xu Y J,Qiu S F,et al. Analysis on clinical characteristics and influencing Factors of patients with locoregionally advanced nasopharyngeal carcinoma[J].Asian Pac J Cancer Prev,2015,16(10):4393-4399.DOI:10.7314/APJCP.2015.16.10.4393.
[15] Adham M,Greijer AE,Verkuijlen SAWM,et al. Epstein-Barr virus DNA load in nasopharyngeal brushings and whole blood in nasopharyngeal carcinoma patients before and after treatment[J].Clin Cancer Res,2013,19(8):2175-2186.DOI:10.1158/1078-0432.CCR-12-2897.
[16] Guo SS,Tang LQ,Zhang L,et al. The impact of the cumulative dose of cisplatin during concurrent chemoradiotherapy on the clinical outcomes of patients with advanced-stage nasopharyngeal carcinoma in an era of intensity-modulated radiotherapy[J].BMC Cancer,2015,15(1):977.DOI:10.1186/s12885-015-1964-8.
[17] 刘帅,韩非,陈春燕,等.不同剂量顺铂同步联合调强放射治疗鼻咽癌的Ⅱ期前瞻性随机对照研究[J].中华肿瘤杂志,2014,36(10):778-782.DOI:10.3760/cma.j.issn.0253-3766.2014.10.013.
Liu S,Han F,Chen CY,et al. Concurrent chemotherapy with different dose regimens of cisplatin for nasopharyngeal carcinoma using intensity-modulated radiation therapy:a phase Ⅱ prospective randomized controlled trial[J].Chin J Oncol,2014,36(10):778-782.DOI:10.3760/cma.j.issn.0253-3766.2014.10.013.
[18] 侯雪,张力,赵充,等.血浆EB病毒DNA浓度预测鼻咽癌远处转移的研究[J].癌症,2006,25(7):785-792.DOI:10.3321/j.issn:1000-467X.2006.07.001.
Hou X,Zhang L,Zhao C,et al. Prognostic impact of plasma Epstein-Barr virus DNA concentration on distant metastasis in nasopharyngeal carcinoma[J].Chin J Cancer,2006,25(7):785-792.DOI:10.3321/j.issn:1000-467X.2006.07.001.
[19] Zhang Y,Li WF,Mao YP,et al. Risk stratification based on change in plasma Epstein-Barr virus DNA load after treatment in nasopharyngeal carcinoma[J].Oncotarget,2016,7(8):9576-9585.DOI:10.18632/oncotarget.7083.